Key Takeaways & Executive Findings
- •• • Clinical improvement at day 28 occurred in 51.9% of CP recipients versus 43.1% of controls (risk difference 8.8 percentage points; 95% CI -10.4 to 28.0; p=0.32), indicating no statistically significant benefit, yet a trend toward harm reduction. • • All-cause mortality at day 28 was 15.4% in the CP group versus 23.5% in the control group (hazard ratio 0.65; 95% CI 0.29 to 1.46; p=0.30), suggesting a potential mortality benefit that did not reach significance. • • Neutralizing antibody titers ≥1:80 at day 3 were achieved in 82.7% of CP recipients versus 21.6% of controls (p<0.001), confirming robust passive immunization. • • No significant differences in adverse events were observed between groups, supporting the safety profile of CP therapy in this critically ill population.
Abstract
Background: Convalescent plasma (CP) therapy has been proposed as a treatment for severe coronavirus disease 2019 (COVID-19), but evidence from randomized controlled trials (RCTs) is limited. Methods: In this multicenter, open-label, RCT, we randomly assigned hospitalized adults with severe COVID-19 pneumonia to receive either CP with standard care or standard care alone. The primary outcome was clinical improvement at day 28, defined as a two-point improvement on a seven-category ordinal scale or discharge. Secondary outcomes included all-cause mortality, time to clinical improvement, and safety. Results: A total of 103 patients were randomized (52 to CP, 51 to control). The median age was 70 years, and 58% were male. At day 28, clinical improvement occurred in 51.9% of CP recipients versus 43.1% of controls (risk difference 8.8 percentage points; 95% CI -10.4 to 28.0; p=0.32). All-cause mortality at day 28 was 15.4% in the CP group versus 23.5% in the control group (hazard ratio 0.65; 95% CI 0.29 to 1.46; p=0.30). CP therapy was associated with a higher rate of neutralizing antibody titers ≥1:80 at day 3 (82.7% vs. 21.6%, p<0.001). No significant differences in adverse events were observed. Conclusions: Among patients with severe COVID-19, CP therapy did not result in a statistically significant improvement in clinical outcomes at day 28, but it was safe and associated with increased neutralizing antibody titers. Larger trials are needed to confirm potential benefits.
1. Introduction
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has precipitated a global health crisis, with severe COVID-19 manifesting as acute respiratory distress syndrome (ARDS) and multi-organ failure. Despite advances in supportive care, including corticosteroids and immunomodulators, mortality remains substantial, particularly among the elderly and those with comorbidities. Convalescent plasma (CP) therapy, a century-old passive immunization strategy, has been repurposed as a potential treatment, leveraging neutralizing antibodies from recovered patients to suppress viremia and modulate the inflammatory cascade. However, early observational studies yielded conflicting results, and the lack of controlled data hindered definitive conclusions.
This multicenter, randomized controlled trial was designed to address the critical evidence gap by rigorously evaluating the efficacy and safety of CP in severe COVID-19. The protocol employed a pragmatic design, enrolling patients with confirmed severe pneumonia and randomizing them to receive CP with a neutralizing antibody titer of at least 1:80, alongside standard care. The primary endpoint, clinical improvement at day 28, was chosen to capture meaningful patient-centered outcomes. By comparing CP against standard care alone, this study aims to provide definitive data on whether CP confers a measurable benefit, thereby informing clinical guidelines and pandemic preparedness strategies.
Loading authentic research manuscript (Pages 1–5)...
LI Wei, ZHANG Hong, WANG Fang, et al. (2025). Efficacy and Safety of Convalescent Plasma Therapy for Severe COVID-19: A Multicenter, Randomized Controlled Trial. Chinese Journal of New Drugs. https://doi.org/pub_80__articleID_235
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What was the neutralizing antibody titer threshold for CP units, and how did it affect the observed clinical response?
CP units were required to have a neutralizing antibody titer of at least 1:80. At day 3, 82.7% of CP recipients achieved titers ≥1:80, compared to 21.6% in controls (p<0.001). This robust seroconversion did not translate into a statistically significant clinical improvement, suggesting that while passive immunity was achieved, other factors such as timing, disease severity, and underlying immune response may modulate efficacy.
What was the all-cause mortality rate at day 28, and was there a significant difference between groups?
All-cause mortality at day 28 was 15.4% in the CP group versus 23.5% in the control group, yielding a hazard ratio of 0.65 (95% CI 0.29 to 1.46; p=0.30). Although the point estimate suggests a 35% relative reduction in mortality, the confidence interval is wide and includes 1, indicating that the difference was not statistically significant. This may be due to the small sample size and warrants confirmation in larger trials.
Were there any significant differences in adverse events between the CP and control groups?
No significant differences in adverse events were observed between the CP and control groups. The safety profile of CP was comparable to standard care, with no increase in transfusion reactions, thromboembolic events, or other serious adverse events. This supports the feasibility of CP as a therapeutic option in severe COVID-19.
How was the primary outcome of clinical improvement defined, and what was the observed rate?
Clinical improvement was defined as a two-point improvement on a seven-category ordinal scale or discharge from the hospital. At day 28, 51.9% of CP recipients achieved this endpoint versus 43.1% of controls, with a risk difference of 8.8 percentage points (95% CI -10.4 to 28.0; p=0.32). The lack of statistical significance suggests that CP did not provide a clear benefit over standard care in this population.
What were the inclusion criteria for patients, and how might they have influenced the results?
Inclusion criteria included adults with laboratory-confirmed SARS-CoV-2 infection, severe pneumonia (oxygen saturation ≤93% or PaO2/FiO2 <300 mmHg), and symptom onset within 10 days. The median age was 70 years, and 58% were male. The severity of illness and advanced age may have contributed to the high mortality rate and limited the potential benefit of CP, as earlier intervention might be more effective.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.